Roche jumps ship on AC Immune

<span style="mso-ansi-language:EN-GB" lang="EN-GB">Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with <link https://www.acimmune.com _blank>AC Immune SA</link> after disappointing study results. It has handed the global rights to Crenezumab and […]

Deregulation of new genomic techniques before decision

After the EU Parliament's Agriculture (AGRI) Committee called for a patent ban on NGT-1 breeds on 8 January, the ENVI Committee will give its input to the EU Commissions draft […]

Amsilk partners with 21st.BIO

AMSilk GmbH and Danish 21st.BIO A/S announce partnership to accelerate the production of advanced materials made from spider silk-based proteins.

Onera Health raises US$32m in Series C round

Sleep diagnostics specialist Onera Health NV has closed a €30m (US$32m) Series C financing round co-led by EQT Life Sciences and Gimv.

Spexis sells antibiotics programme to Basilea

Macrocycle library secialist Spexis AG is set to sell a preclinical antibiotics programme afor CHF2m to Basilea Pharmaceutica Ltd.

Finnish Enifer Oy secures €12m grant to scale up

Microbial production specialist Enifer has secured a €12m grant from Business Finland to build a mycoprotein ingredient factory with a capacity of 300,000 tonnes annually.

Mogu Srl raises €11m to scale mycelium technology

Italian mycelium specialist Mogu Srl has closed a €11m Series A financing co-led by CDP Venture Capital and the&nbsp; European Circular Bioeconomy Fund (ECBF VC)

Novartis AG to buy immunology specialist Calypso Biotech BV

<a title="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1630-2-24167-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Calypso Biotech BV</a> has entered into an agreement to be acquired by Novartis AG, which will pay. Calypso’s US$250m upfront upon closing plus of up […]

GLP1 agonists: FDA investigates suicide risk

Following in the footsteps of the European Medicines Agency (EMA), the US FDA is now also investigating the side effects of obesity blockbusters.<br /><br /><br />